Esperion Therapeutics Merger Agreement Filed

Esperion Therapeutics, Inc. filed an SEC exhibit containing an Agreement and Plan of Merger dated March 2, 2026. The document sets out merger mechanics, including conversion of securities, closing payments, and a post-closing merger consideration adjustment.

It also describes contingent merger consideration, including milestone payments, earnout payments, and licensing-revenue-related payments, along with reporting obligations, audit rights, and divestiture provisions tied to contingent consideration.

The filing further includes standard merger covenants and conditions to closing, including governmental body filings and antitrust-related obligations.